YOUR BRAND · YOUR CUSTOMERS · YOUR AI BUSINESS

Sell AI employees under your own brand.

Agentic AI Comparison:
Paige AI vs Palo Alto Networks Prisma AIRS

Paige AI - AI toolvsPalo Alto Networks Prisma AIRS logo

Introduction

Paige, now a Tempus company, provides digital-pathology AI and research technology; its Alba copilot is available in beta trials. Prisma AIRS provides security controls for enterprise AI applications and agents. Ratings are subjective editorial opinions for each product’s stated purpose, not measured benchmarks.

Overview

Paige AI

Paige, now a Tempus company, provides digital-pathology AI and research technology; its Alba copilot is available in beta trials. Paige offers tissue-image analysis applications, foundation models and Alba summaries, image assistance and report drafting. Product-specific clinical labeling matters: Alba is informational, and research-only workflows are not diagnostic services.

Palo Alto Networks Prisma AIRS

Prisma AIRS provides security controls for enterprise AI applications and agents. Its portfolio covers discovery, posture, testing and runtime protection. Security teams select controls for the deployed models, applications and agent actions.

Editorial ratings · 1–10, higher is better

These scores express our judgement of the cited product facts. They are not measured performance benchmarks. Each product is assessed for its stated purpose; a higher score does not make different workflows interchangeable.

Evidence gaps lower confidence and affect the relevant judgement. Unknown pricing does not mean free access. Research prototypes and retired products retain their historical scope, with adoption ratings reflecting current access.

Ratings assessed: 2026-11-10. Source verification dates may differ.

Documented capability: How useful and complete is the documented workflow for the product's stated purpose?

  • 1–2: No usable current workflow established, or only an unsupported promise.
  • 3–4: Historical, experimental or very limited workflow; substantial delivery gaps.
  • 5–6: Concrete but narrow workflow, or promising research requiring specialist review.
  • 7–8: Substantial documented end-to-end workflow with useful controls or customization.
  • 9–10: Exceptionally complete documented scope and controls; reserve 10 for unusually strong evidence.

Ease of adoption: Can the intended user obtain and set up a usable product today?

  • 1–2: Discontinued, unavailable, waitlisted, or no usable deployment path verified.
  • 3–4: Archived software, restricted research/preorder access or uncertain current service access.
  • 5–6: Developer-managed setup, significant configuration or sales-led implementation.
  • 7–8: Active accessible product with manageable setup for its intended user.
  • 9–10: Straightforward self-service access and setup, with unusually few adoption obstacles.

Value and cost clarity: How attractive and understandable is the cost model for the documented use?

  • 1–2: No current purchasable or usable offer; historical prices cannot support a purchase.
  • 3–4: Material price, entitlement, license or availability uncertainty limits budgeting.
  • 5–6: Plausible value with custom pricing, significant setup costs or incomplete selected-plan terms.
  • 7–8: Useful scope with clear entry pricing/allowances or accessible source, while accounting for running costs.
  • 9–10: Exceptionally accessible and clear cost model for substantial useful scope; never assume free compute.

Integration options: How useful and extensible are the verified user-facing connections for the intended workflow?

  • 1–2: No current user-facing connection verified, or former connections are unavailable.
  • 3–4: Inputs/exports or one focused connection; internal dependencies are not native connectors.
  • 5–6: Useful API, configurable tools or several relevant connections, with limited verified breadth.
  • 7–8: Broad relevant connections or an extensible documented API/MCP/tool ecosystem.
  • 9–10: Extensive documented ecosystem with multiple connection mechanisms and strong task relevance.

Metrics Comparison

Documented capability

Paige AI: 8/10

Evidence confidence: medium

Paige offers tissue-image analysis applications, foundation models and Alba summaries, image assistance and report drafting. Product-specific clinical labeling matters: Alba is informational, and research-only workflows are not diagnostic services.

Palo Alto Networks Prisma AIRS: 8/10

Evidence confidence: medium

Its portfolio covers discovery, posture, testing and runtime protection. Security teams select controls for the deployed models, applications and agent actions.

The scores judge completeness for each stated purpose; different workflows are not interchangeable.

Ease of adoption

Paige AI: 5/10

Evidence confidence: medium

Adoption requires a specialist laboratory or research team, a trial or commercial discussion and validation of the exact application and workflow. Clinicians retain diagnostic decisions.

Palo Alto Networks Prisma AIRS: 5/10

Evidence confidence: medium

Enterprise rollout requires architecture, policy, access and integration work. Teams review alerts and tune controls for their actual applications.

Access, setup and human responsibilities matter alongside features.

Value and cost clarity

Paige AI: 5/10

Evidence confidence: medium

Pricing is arranged with the provider rather than a public self-service plan. Budget for the selected software, slide and data infrastructure, integration and clinical validation.

Palo Alto Networks Prisma AIRS: 4/10

Evidence confidence: medium

Pricing and entitlement depend on the enterprise deployment. Obtain a scoped quote rather than treating the platform as a free agent framework.

Compare the full cost of your intended workflow, including external services and implementation.

Integration options

Paige AI: 6/10

Evidence confidence: medium

Alba brings pathology, radiology and patient-history context together. Paige also documents pathology-system integration; confirm compatibility with your own image, laboratory and hospital systems during scoping.

Palo Alto Networks Prisma AIRS: 8/10

Evidence confidence: medium

API and runtime integration options connect protection to AI workloads. Confirm the specific control, deployment mode and supported environment during scoping.

Choose the connections your workflow needs, rather than counting partner logos.

Conclusions

Paige helps pathology teams analyze medical information. Prisma AIRS helps security teams protect AI systems; their scores do not establish which is better at the other’s task.

Evaluate Paige for professional pathology or computational-pathology research. Select the exact application and permitted use, rather than treating every Paige model or Alba feature as diagnostically cleared.

Evaluate Prisma AIRS for securing AI systems; it serves a different purpose from clinical-pathology assistance.

YOUR BRAND · YOUR CUSTOMERS · YOUR AI BUSINESS

Sell AI employees under your own brand.

Give businesses AI teams that own ongoing roles. Set your pricing, delegate routine coordination and build a recurring service.